Caribou, MaxCyte enter CRISPR license agreement

By The Science Advisory Board staff writers

May 7, 2020 -- Caribou Biosciences and MaxCyte have announced a clinical and commercial license agreement for the development of Carbiou's CAR-T cell therapy program.

Under the agreement, Caribou gains rights to the use of MaxCyte's Flow Electroporation technology and ExPert platform for advancement of its CRISPR gene-edited allogenic T-cell therapy. Caribou will obtain nonexclusive clinical and commercial rights to the platform and in return MaxCyte will receive undisclosed development and approval milestones and sales-based payments in addition to licensing fees.
Copyright © 2020 scienceboard.net


Conferences
Cell Bio 2021
December 11-15
San Diego, California United States
Antibody Engineering and Therapeutics
December 13-17
San Diego, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter